Daily Market Research Report

February 25, 2026

Alpha Signal Monitor

Welcome to your daily pre-market briefing. This report provides key insights on market opportunities and analyst perspectives to help identify potential alpha signals.

Today's Coverage: - Gold ETF Outlook: Institutional perspectives on gold-backed ETFs - Stock Ratings: Latest analyst ratings and target prices for our watchlist - IPO Calendar: Upcoming initial public offerings and market debuts

Watchlist Stocks: AAPL, MSFT, GOOGL, AMZN, NVDA, META, TSLA, AVGO, TSM

This report is generated using advanced AI research capabilities with real-time market data access.

Gold ETFs (GLD, IAU, BAR): Cross‑Institution Outlook as of February 25, 2026

Trading Idea: Buy Rationale (TL;DR): Most top houses expect higher gold into late‑2026 on persistent official‑sector accumulation and improving private/ETF demand as real rates drift lower; upside targets cluster around $5,000/oz with Goldman at $5,400 by year‑end 2026, supporting long exposure via GLD/IAU/BAR. (straitstimes.com)

Banks highlight a structural shift toward gold in reserves post‑2022, resilient central‑bank buying, and a prospective decline in real yields that can re‑accelerate ETF demand; downside scenarios revolve around fewer Fed cuts, a stronger USD, and volatility temporarily sidelining central banks. (goldmansachs.com)

Key Drivers - Structural central‑bank accumulation (EM reserve diversification) seen persisting through 2026–27. (goldmansachs.com) - Lower real rates and a softer USD would improve the carry trade‑off for non‑yielding gold and support ETF inflows. (ubs.com) - Private‑sector/ETF demand is rising alongside official buying, tightening the balance and underpinning prices. (marketwatch.com) - Geopolitical/trade‑policy uncertainty and concerns over fiscal sustainability reinforce hedging demand. (investing.com)

Risk Considerations - Fewer or delayed Fed cuts and/or a stronger USD could sap momentum. (morganstanley.com) - High volatility may pause central‑bank purchases near highs, reducing a key demand pillar tactically. (businessinsider.com) - Positioning washouts after crowded longs can trigger sharp pullbacks. (goldmansachs.com) - Price‑sensitive physical/jewelry demand erosion at elevated price levels. (morganstanley.com)

Bias long GLD/IAU/BAR into late‑2026; scale in and buy dips given path‑dependent volatility. For portfolio construction, a mid‑single‑digit allocation to gold is consistent with CIO guidance; choose IAU/BAR for fee efficiency and GLD for depth/liquidity. Reassess if Fed path/US dollar diverge materially or if official‑sector demand falters. (ubs.com)

Stock Ratings

Error retrieving stock ratings information: Request timed out.

IPO Calendar

Timeframe: February 26, 2026 – March 26, 2026 (US IPOs)

Expect a lighter deal pace at the start of March as issuers finalize audited 2025 financials, with activity skewed to biopharma and carve‑outs, and several micro‑caps likely to slot in late. Recent week‑ahead updates flagged a February lull but pointed to a near‑term reopening led by healthcare (e.g., Generate Biomedicines) and Medtronic’s diabetes carve‑out MiniMed beginning its roadshow; valuation sensitivity remains high after Clear Street’s pulled deal. (renaissancecapital.com)

MiniMed Group, Inc. (Medtronic Diabetes carve‑out) (MMED)

• Price range: $25.00 – $28.00
• Shares offered: 28,000,000 primary (30‑day option up to 4,200,000)
• Exchange: Nasdaq Global Select
• Lead underwriters: Goldman Sachs & Co. LLC, BofA Securities, Citigroup, Morgan Stanley
• Business summary: Global diabetes‑technology business being separated from Medtronic; portfolio includes insulin pumps, continuous glucose monitors, algorithms and connected software/services for intensive insulin therapy.
• Notes: Roadshow launched February 24, 2026; timing to price/list is subject to market conditions. Medtronic expected to retain ~90% voting control post‑IPO (controlled‑company status).
• Sources: https://news.medtronic.com/2026-02-24-MiniMed-announces-launch-of-IPO-roadshow, https://www.sec.gov/Archives/edgar/data/2062583/000162828026010862/minimedgroupincs-1a2.htm, https://www.sec.gov/Archives/edgar/data/2062583/000162828025058231/minimedgroupincs-1.htm

Generate Biomedicines, Inc. (GENB)

• Expected listing date: 2026-02-27
• Price range: $15.00 – $17.00
• Shares offered: 25,000,000 (plus 30‑day option indicated in filings)
• Exchange: Nasdaq
• Lead underwriters: Goldman Sachs & Co. LLC, Morgan Stanley, Piper Sandler, Guggenheim Securities, Cantor Fitzgerald
• Business summary: AI‑enabled protein‑design biotech; lead asset GB‑0895 (anti‑TSLP) is in Phase 3 trials for severe asthma, with proceeds primarily to fund late‑stage development.
• Notes: Terms set February 23, 2026; expected to price/list late this week subject to market conditions.
• Sources: https://www.renaissancecapital.com/IPO-Center/News/117178/Asthma-focused-AI-biotech-Generate-Biomedicines-sets-terms-for-%24400-million, https://www.fiercebiotech.com/biotech/generate-plans-425m-ipo-bankroll-antibodys-phase-3-asthma-trials, https://www.sec.gov/Archives/edgar/data/0002100782/000119312526037799/ck0002100782-20260204.htm

Salspera, Inc. (TKVA)

• Price range: $14.00 – $16.00
• Shares offered: 5,700,000
• Exchange: Nasdaq
• Lead underwriters: Kingswood Capital Markets
• Business summary: Clinical‑stage immuno‑oncology company developing live biotherapeutics; lead candidate Saltikva (engineered, orally administered Salmonella‑IL2) targets solid tumors, initially metastatic pancreatic cancer.
• Notes: Filed and set terms in late February; launch/pricing window likely near‑term pending market conditions.
• Sources: https://www.sec.gov/Archives/edgar/data/2084032/000121390026019404/0001213900-26-019404-index.htm, https://www.renaissancecapital.com/IPO-Center/News/117206/Immuno-oncology-biotech-Salspera-sets-terms-for-%2485-million-IPO

Swarmer, Inc. (SWMR)

• Expected listing date: 2026-02-26
• Price range: $4.00 – $6.00
• Shares offered: 3,000,000
• Exchange: Nasdaq Capital Market
• Lead underwriters: Lucid Capital Markets
• Business summary: Defense‑tech software firm developing Trident OS, an embedded operating system enabling coordination and autonomy for large‑scale drone swarms; initial deployments have focused on military use‑cases.
• Notes: Micro‑cap IPO; timing subject to final exchange approvals and market conditions.
• Sources: https://www.renaissancecapital.com/IPO-Center/News/117150/Autonomous-drone-operating-software-firm-Swarmer-sets-terms-for-%2415-million, https://www.investing.com/news/stock-market-news/swarmer-files-for-ipo-to-list-on-nasdaq-under-ticker-swmr-432SI-4479890

Student Living EduVation (Holdings) Corp. (SDLV)

• Price range: $4.00 (fixed)
• Shares offered: 3,800,000
• Exchange: Nasdaq Capital Market
• Lead underwriters: D. Boral Capital
• Business summary: Hong Kong–based student‑housing operator providing dormitory accommodation, property management and education‑advisory referral services; manages five facilities with near‑full occupancy.
• Notes: Foreign issuer listing in the US; terms disclosed, listing date TBA.
• Sources: https://www.sec.gov/Archives/edgar/data/2083843/000118518525002172/studentf1121125.htm, https://www.renaissancecapital.com/IPO-Center/News/117105/Hong-Kong-student-dorm-provider-Student-Living-EduVation-sets-terms-for-%2415, https://hk.investing.com/news/stock-market-news/article-1321783

Motive Technologies, Inc. (MTVE)

• Exchange: NYSE
• Lead underwriters: J.P. Morgan, Citigroup, Barclays, Jefferies
• Business summary: AI platform for physical‑operations management across fleets, equipment, spend and workforce; serves ~100k customers across logistics, construction, energy and other industrial end‑markets.
• Notes: Public S‑1 filed December 23, 2025; eligible to launch a roadshow on short notice depending on market tone; no terms/date yet.
• Sources: https://gomotive.com/motive-files-registration-statement-for-proposed-initial-public-offering/, https://www.renaissancecapital.com/IPO-Center/News/115794/Fleet-management-software-provider-Motive-Technologies-files-for-a-%24100-mil, https://www.investing.com/news/stock-market-news/fleet-management-firm-motive-technologies-reveals-revenue-growth-in-us-ipo-paperwork-4422050

Grayscale Investments, Inc. (GRAY)

• Exchange: NYSE
• Lead underwriters: Morgan Stanley, BofA Securities, Jefferies, Cantor Fitzgerald
• Business summary: Crypto‑asset manager (operator of GBTC and other crypto investment products) pursuing a traditional US IPO; proceeds expected to support growth of its digital‑asset investment platform.
• Notes: Public S‑1 filed November 13, 2025; timing contingent on SEC review and market conditions; no terms or date yet.
• Sources: https://www.globenewswire.com/news-release/2025/11/13/3187426/0/en/Grayscale-Investments-Announces-Public-Filing-of-Registration-Statement-for-Proposed-Initial-Public-Offering.html, https://www.sec.gov/Archives/edgar/data/2073548/000119312525279127/ck0002073548-20251113.htm

Clear Street Group, Inc. (CLRS)

• Price range: Most recent public range before postponement: $26.00 – $28.00 (cut from $40.00 – $44.00)
• Shares offered: Most recent public size before postponement: 13,000,000 primary (cut from 23,809,524)
• Exchange: Nasdaq Global Select (proposed)
• Lead underwriters: Goldman Sachs & Co. LLC, BofA Securities, Morgan Stanley, UBS Investment Bank, Clear Street LLC
• Business summary: Cloud‑native capital‑markets infrastructure platform spanning prime brokerage, clearing, custody and financing.
• Notes: Deal was postponed on February 13, 2026 amid volatility; syndicate and terms may change upon relaunch; included here as a watch‑list candidate for a potential March window if markets stabilize.
• Sources: https://www.investing.com/news/stock-market-news/wall-street-broker-clear-street-cuts-us-ipo-valuation-target-to-72-billion-4502653, https://www.ft.com/content/e0c71b94-b761-496c-a251-f106cbb9353a, https://www.sec.gov/Archives/edgar/data/1881567/000119312526043602/d39893ds1a.htm

IPO calendars change quickly. Dates often firm up only after roadshows launch; micro‑caps and SPACs can post with minimal lead time; terms may be revised or offerings postponed. Always re‑check issuer press releases, exchange calendars and SEC EDGAR the day before expected pricing.

Sources

• IPO Calendar: https://gomotive.com/motive-files-registration-statement-for-proposed-initial-public-offering/, https://hk.investing.com/news/stock-market-news/article-1321783, https://news.medtronic.com/2026-02-24-MiniMed-announces-launch-of-IPO-roadshow, https://www.fiercebiotech.com/biotech/generate-plans-425m-ipo-bankroll-antibodys-phase-3-asthma-trials, https://www.ft.com/content/e0c71b94-b761-496c-a251-f106cbb9353a, https://www.globenewswire.com/news-release/2025/11/13/3187426/0/en/Grayscale-Investments-Announces-Public-Filing-of-Registration-Statement-for-Proposed-Initial-Public-Offering.html, https://www.investing.com/news/stock-market-news/fleet-management-firm-motive-technologies-reveals-revenue-growth-in-us-ipo-paperwork-4422050, https://www.investing.com/news/stock-market-news/swarmer-files-for-ipo-to-list-on-nasdaq-under-ticker-swmr-432SI-4479890, https://www.investing.com/news/stock-market-news/wall-street-broker-clear-street-cuts-us-ipo-valuation-target-to-72-billion-4502653, https://www.renaissancecapital.com/IPO-Center/News/115794/Fleet-management-software-provider-Motive-Technologies-files-for-a-%24100-mil, https://www.renaissancecapital.com/IPO-Center/News/117045/US-IPO-Week-Ahead-Markets-set-for-a-quiet-week-post-Presidents%25E2%2580%2599-Day?utm_source=openai, https://www.renaissancecapital.com/IPO-Center/News/117105/Hong-Kong-student-dorm-provider-Student-Living-EduVation-sets-terms-for-%2415, https://www.renaissancecapital.com/IPO-Center/News/117150/Autonomous-drone-operating-software-firm-Swarmer-sets-terms-for-%2415-million, https://www.renaissancecapital.com/IPO-Center/News/117178/Asthma-focused-AI-biotech-Generate-Biomedicines-sets-terms-for-%24400-million, https://www.renaissancecapital.com/IPO-Center/News/117206/Immuno-oncology-biotech-Salspera-sets-terms-for-%2485-million-IPO, https://www.sec.gov/Archives/edgar/data/0002100782/000119312526037799/ck0002100782-20260204.htm, https://www.sec.gov/Archives/edgar/data/1881567/000119312526043602/d39893ds1a.htm, https://www.sec.gov/Archives/edgar/data/2062583/000162828025058231/minimedgroupincs-1.htm, https://www.sec.gov/Archives/edgar/data/2062583/000162828026010862/minimedgroupincs-1a2.htm, https://www.sec.gov/Archives/edgar/data/2073548/000119312525279127/ck0002073548-20251113.htm, https://www.sec.gov/Archives/edgar/data/2083843/000118518525002172/studentf1121125.htm, https://www.sec.gov/Archives/edgar/data/2084032/000121390026019404/0001213900-26-019404-index.htm

Disclaimer

This research report is for informational purposes only and does not constitute investment advice. All information is sourced from publicly available data and should be verified independently. Past performance does not guarantee future results.

Generated on: 2026-02-25 at 11:49 UTC
Source: Alpha Signal Monitor - Automated Research System
Contact: For questions about this report, please contact your Alpha Signal Monitor administrator.

Powered by Alpha Signal Monitor | Market Intelligence Through AI